Veterinary pharmaceutical company Dechra announced Thursday the appointment of Anne-Francoise Nesmes as Chief Financial Officer.
Nesmes joins the company on April 22nd from GlaxoSmithKline where she has worked since 1997 in a number of finance roles including Senior Vice-President, Finance of Vaccines in Belgium.
She has also held finance positions with John Crane, Tetra Pak, ADP and Caterpillar UK.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The French national, who holds an MBA from Henley Management College and a Master in Management Sciences from Grenoble Business School, started her career in the UK before moving to Belgium, Sweden, and the US.
She will relocate to the UK on taking up her position with the group.
Mike Redmond, Chairman of Dechra, said: "We are delighted that Anne-Francoise is joining Dechra. She is a high calibre finance professional who also has valuable international, pharmaceutical, manufacturing and commercial experience. She will be a welcome addition to the executive team.
"I, and the rest of the board, look forward to working with Anne-Francoise to continue to progress our strategy of delivering a high growth, cash generative, specialist veterinary products business."
RD
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
-
What does Rachel Reeves’s plan for growth mean for UK investors?Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
